AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-12. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== Patents and regulatory exclusions === GLP-1 drugs are protected by patents and regulatory exclusivities, which delay generic competitors and keep prices high. The drugs have a median of 20 patents. These patents have protection periods averaging 18 years. The patents apply not only to the drugs but also to injection devices, delivery systems, and other components. Overlapping patents make it hard for generic manufacturers to enter the market. This creates a tradeoff between short-term affordability and long-term pharmaceutical innovation. Semaglutide's main patent expired in 2026 in several countries, but lasts until the early 2030s in many others.
== Pathophysiology == The human skin consists of two layers: an outermost layer called the epidermis and a layer underneath called the dermis. In individuals with healthy skin, there are protein anchors between these two layers (dermo-epidermal junction) that prevent them from moving independently from one another (shearing). In people born with EB, the two skin layers lack the protein anchors that hold them together, resulting in extremely fragile skin—even minor mechanical friction (like rubbing or pressure) or trauma will separate the layers of the skin and form blisters and painful sores. EB individuals manifest unremitting skin blistering that evolves into chronic wounds, inflammation, and fibrosis. People with EB have compared the sores with third-degree burns. Furthermore, as a complication of the chronic skin damage, people with EB have an increased risk of malignancies (cancers) of the skin. Virtually any organ lined or covered by epithelium may be injured in inherited EB. External eye, esophagus, upper airway, and genitourinary tract are the epithelial surfaced tissues that are at particular risk.
Collagen α-1 (XXIII) chain is a protein encoded by COL23A1 gene, which is located on chromosome 5q35 in humans, and on chromosome 11B1+2 in mice. The location of this gene was discovered by genomic sequence analysis. Collagen XXIII is a type II transmembrane protein and the fourth in the subfamily of non-fibrillar transmembranous collagens. This kind of collagens have a single pass hydrophobic transmembrane domain. The molecule of collagen XXIII can be found either in membrane-bond form or in shed form. Type XXIII collagen is expressed in both adult tissues and developing organs. It can be found in the epidermis and other epithelia such as those in tongue, gut and lung, but also in the brain, the kidney and the cornea. It has been shown that in prostate collagen XXIII expression is associated with tumor progression. The functions of collagen XXIII are still unknown, although it is believed that they could be similar to other transmembrane proteins, such as collagen XIII.
== Autologous grafts == Autologous grafts are used to transfer tissue from one site to another on the same body. The use of autologous grafts prevents transplantation rejection reactions. Grafts used for oral reconstruction are preferably taken from the oral cavity itself (such as gingival and palatal grafts). However, their limited availability and small size leads to the use of either skin transplants or intestinal mucosa to be able to cover bigger defects. Other than tissue shortage, donor site morbidity is a common problem that may occur when using autologous grafts. When tissue is obtained from somewhere other than the oral cavity (such as the intestine or skin) there is a risk of the graft not being able to lose its original donor tissue characteristics. For example, skin grafts are often taken from the radial forearm or lateral upper arm when covering more extensive defects. A positive aspect of using skin grafts is the large availability of skin. However, skin grafts differ from oral mucosa in: consistency, color and keratinization pattern. The transplanted skin graft often continues to grow hair in the oral cavity.
Sources: en.wikipedia.org
Fourteen isotopes of nobelium are known, with mass numbers 248–260 and 262; all are radioactive. Additionally, seventeen nuclear isomers are known, their mass numbers range between 250 to 256. Of these, the longest-lived isotope is 259No with a half-life of 58 minutes, and the longest-lived isomer is 251mNo with a half-life of 1.02 seconds. However, the still undiscovered isotope 261No is predicted to have a still longer half-life of 3 hours. Additionally, the shorter-lived 255No (half-life 3.52 minutes) is more often used in chemical experimentation because it can be produced in larger quantities from irradiation of californium-249 with carbon-12 ions. After 259No and 255No, the next most stable nobelium isotopes are 253No (half-life 1.57 minutes), 254No (51.2 seconds), 257No (24.5 seconds), 256No (2.91 seconds), and 252No (2.467 seconds). All of the remaining nobelium isotopes have half-lives that are less than a second, and the shortest-lived known nobelium isotope (248No) has a half-life of less than 2 microseconds. The isotope 254No is especially interesting theoretically as it is in the middle of a series of prolate nuclei from 231Pa to 279Rg, and the formation of its nuclear isomers (of which two are known) is controlled by proton orbitals such as 2f5/2 which come just above the spherical proton shell; it can be synthesized in the reaction of 208Pb with 48Ca. The half-lives of nobelium isotopes increase smoothly from 250No to 253No.
Handheld electronics mostly use lithium polymer batteries (with a polymer gel as an electrolyte), a lithium cobalt oxide (LiCoO2) cathode material, and a graphite anode, which together offer high energy density. Lithium iron phosphate (LiFePO4), lithium manganese oxide (LiMn2O4 spinel, or Li2MnO3-based lithium-rich layered materials, LMR-NMC), and lithium nickel manganese cobalt oxide (LiNiMnCoO2 or NMC) may offer longer life and a higher discharge rate. NMC and its derivatives are widely used in the electrification of transport, one of the main technologies (combined with renewable energy) for reducing greenhouse gas emissions from vehicles. Lithium nickel cobalt aluminum oxide (NCA) is another high-energy lithium-ion chemistry commonly used in electric vehicle batteries.
As minor planet discoveries are confirmed, they are given a permanent number by the IAU's Minor Planet Center (MPC), and the discoverers can then submit names for them, following the IAU's naming conventions. The list below concerns those minor planets in the specified number-range that have received names, and explains the meanings of those names. Official naming citations of newly named small Solar System bodies are approved and published in a bulletin by IAU's Working Group for Small Bodies Nomenclature (WGSBN). Before May 2021, citations were published in MPC's Minor Planet Circulars for many decades. Recent citations can also be found on the JPL Small-Body Database (SBDB). Until his death in 2016, German astronomer Lutz D. Schmadel compiled these citations into the Dictionary of Minor Planet Names (DMP) and regularly updated the collection. Based on Paul Herget's The Names of the Minor Planets, Schmadel also researched the unclear origin of numerous asteroids, most of which had been named prior to World War II. This article incorporates text from this source, which is in the public domain: SBDB New namings may only be added to this list below after official publication as the preannouncement of names is condemned. The WGSBN publishes a comprehensive guideline for the naming rules of non-cometary small Solar System bodies.
Sources: en.wikipedia.org
The first pictorial evidence for cheesemaking was found on a frieze at the Temple of the Great Goddess of Life, Ninhursag, in Mesopotamia in the Fertile Crescent – a region which covers modern day Iraq – and is 5,000 years old. The frieze depicts priests engaged in the production of cow dairy and perhaps creating curd mixture somewhat similar to cottage cheese. A fictional story on the origin of cheese was taken from Homer's Odyssey, in which the poet describes how the Cyclops, Polyphemus, made cheese by storing milk in animal stomachs. The enzyme rennin from animals stomachs induces a coagulation process separating the curds from the whey. As Rome expanded its empire, it spread the knowledge of cheese, discovering many new forms. The Romans introduced cheesemaking to England. Over centuries, European farmers made farmhouse cheeses using fermented-soured milk, then separated the whey from curds as an early form of cottage cheese.
== External links == The MEROPS online database for peptidases and their inhibitors: I39.001[link removed] alpha+2-Macroglobulin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) A2M human gene location in the UCSC Genome Browser. A2M human gene details in the UCSC Genome Browser.
== Further reading == Ortsfamilienbücher. In: Wolfgang Ribbe, Eckart Henning: Taschenbuch für Familiengeschichtsforschung. 12th edition. Degener, Neustadt/Aisch 2001, pp. 306–340, ISBN 3-7686-1062-4 Janet Few, Ten Steps to a One-Place Study, Blue Poppy Publishing 2020, ISBN 978-1911438182
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.